Pro-Dex, Inc. (NASDAQ:PDEX - Get Free Report) Director Raymond E. Cabillot sold 3,096 shares of the stock in a transaction on Wednesday, March 26th. The stock was sold at an average price of $50.13, for a total value of $155,202.48. Following the completion of the sale, the director now directly owns 279,787 shares in the company, valued at $14,025,722.31. This represents a 1.09 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Pro-Dex Stock Performance
Shares of NASDAQ:PDEX traded up $0.13 during trading on Monday, hitting $48.36. 8,656 shares of the stock were exchanged, compared to its average volume of 22,167. The company's fifty day simple moving average is $40.21 and its 200-day simple moving average is $40.09. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.44 and a current ratio of 2.58. The company has a market capitalization of $157.70 million, a price-to-earnings ratio of 24.29 and a beta of 0.68. Pro-Dex, Inc. has a 1-year low of $16.84 and a 1-year high of $59.60.
Pro-Dex (NASDAQ:PDEX - Get Free Report) last posted its earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 EPS for the quarter, topping the consensus estimate of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. Sell-side analysts expect that Pro-Dex, Inc. will post 2 EPS for the current fiscal year.
Hedge Funds Weigh In On Pro-Dex
Several large investors have recently made changes to their positions in the company. Northern Trust Corp lifted its holdings in Pro-Dex by 14.1% in the fourth quarter. Northern Trust Corp now owns 35,754 shares of the medical instruments supplier's stock valued at $1,672,000 after buying an additional 4,426 shares during the period. Geode Capital Management LLC boosted its position in shares of Pro-Dex by 9.1% in the 3rd quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier's stock worth $819,000 after purchasing an additional 2,296 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Pro-Dex by 2.2% during the third quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier's stock worth $740,000 after purchasing an additional 529 shares during the period. EAM Investors LLC bought a new stake in Pro-Dex in the fourth quarter valued at about $1,047,000. Finally, O Shaughnessy Asset Management LLC acquired a new position in Pro-Dex in the fourth quarter valued at about $995,000. Institutional investors and hedge funds own 15.28% of the company's stock.
Wall Street Analysts Forecast Growth
Separately, StockNews.com cut Pro-Dex from a "buy" rating to a "hold" rating in a research note on Wednesday, March 12th.
Read Our Latest Stock Report on PDEX
About Pro-Dex
(
Get Free Report)
Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.
Recommended Stories
Before you consider Pro-Dex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pro-Dex wasn't on the list.
While Pro-Dex currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
